...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>European review for medical and pharmacological sciences. >Effects of atorvastatin combined with trimetazidine on myocardial injury and inflammatory mediator in unstable angina patients during perioperative of percutaneous coronary intervention
【24h】

Effects of atorvastatin combined with trimetazidine on myocardial injury and inflammatory mediator in unstable angina patients during perioperative of percutaneous coronary intervention

机译：阿托伐他汀联合曲美他嗪对不稳定型心绞痛患者经皮冠状动脉介入治疗围手术期心肌损伤和炎症介质的影响

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

OBJECTIVE: To investigate the effects of atorvastatin combined with trimetazidine on periprocedural myocardial injury and serum inflammatory mediators in unstable angina pectoris (UAP) patients following percutaneous coronary intervention (PCI) treatment. PATIENTS AND METHODS: 90 patients with UAP treated with conventional medications and PCI were recruited and were randomly divided into the control group and the experimental group. The control group had 42 patients were treated with atorvastatin alone, while the experimental group had 48 cases treated with atorvastatin combined with trimetazidine. All the patients were checked the preoperative 24h and postoperative 24h PCI concentrations of cardiac troponin I (cTnI), hypersensitive C-reactive protein (hs-CRP), tumor necrosis factor-α (TNF-α), serum interferon-γ (IFN-γ) and interlukin-10 (IL-10). RESULTS: At the pre-PCI stage, every serum factors was no significant difference. 24 hours after the PCI intervention, the occurence of abnormal cTnI level in the experimental group was remarkable reduced than the control group. In the experimental group, the serum levels of TNF-α and IFN-γ significantly decreased (p < 0.05); while IL-10 was increased. In the control group, all the mediators were increased significantly except the hs-CRP (p < 0.05). CONCLUSIONS: No unexpected symptom was found in patients with large dose atorvastatin combined with large dose trimetazidine. The administration of conventional medications together with the atorvastatin plus trimetazidine were able to reduce the prevalence of postoperative myocardial injury.
机译：目的：探讨阿托伐他汀联合曲美他嗪对不稳定型心绞痛（UAP）患者经皮冠状动脉介入治疗（PCI）后围手术期心肌损伤和血清炎性介质的影响。患者与方法：招募了90例接受常规药物和PCI治疗的UAP患者，并随机分为对照组和实验组。对照组42例单独接受阿托伐他汀治疗，实验组48例接受阿托伐他汀联合曲美他嗪治疗。所有患者在术前和术后24h均检查了心肌肌钙蛋白I（cTnI），超敏C反应蛋白（hs-CRP），肿瘤坏死因子-α（TNF-α），血清干扰素-γ（IFN-γ）的PCI浓度。 γ）和白介素10（IL-10）。结果：在PCI前阶段，所有血清因素均无显着差异。 PCI干预后24小时，实验组的cTnI水平异常发生率明显低于对照组。实验组血清TNF-α和IFN-γ水平明显降低（p <0.05）。而IL-10升高。在对照组中，除hs-CRP外，所有介质均显着增加（p <0.05）。结论：大剂量阿托伐他汀联合大剂量曲美他嗪的患者未发现意外症状。常规药物与阿托伐他汀加曲美他嗪的联合使用能够降低术后心肌损伤的患病率。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号